³ÉÈË¿ìÊÖ

Most of the provisions of the Public Services Reform (Scotland) Act 2010 relate to the exercise of functions of a particular body. Some of the provisions of the Act apply to more than one body. These include the requirements to provide information on certain expenditure (section 31) and the exercise of functions (section 32) and the duties imposed on scrutiny bodies in relation to user focus (section 112) and co-operation (section 114). Where the Act imposes a requirement on a public body (whether specifically in relation to that body or more generally) it is the responsibility of the body itself to comply with the provisions.

This government has a sustained focus on improving the quality of public services and continuous improvement in the performance of our public bodies.

There are a wide range of provisions in the Public Services Reform (Scotland) Act 2010 which apply to both individual and to groups of public bodies. We do not compile information on the compliance of public bodies across all the provisions in the act.

The manufacture of Immucyst has been stopped by the manufacturer, Sanofi Pasteur, and I understand that it is unlikely to resume before late 2013. This product is manufactured in Canada and this is a global problem.

The UK-wide medicines regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA) is working closely with other regulatory authorities in helping to resolve the ongoing manufacturing and quality problems at the Canadian site.

In the UK, there is an alternative licensed product, OncoTICE, manufactured by MSD. Limited supplies of OncoTICE are now available directly from the manufacturer.

The Scottish abdominal aortic aneurysm (AAA) screening programme commenced a planned roll-out in July 2012. It is expected that all NHS boards will offer AAA screening by December 2013. Further information on the programme and roll-out is available at:

.

Information on the number of attendances (new and unplanned returns) that were not admitted/transferred/discharged for at least 18 and 24 hours by NHS Board and by accident and emergency site has been placed in the Scottish Parliamentary Information Centre (Bib. number 54263). This information is shown by financial year, from 2008-09 to 2011-12.

Information for 2007-08 is not included as a full year's worth of data is not available (the accident and emergency data mart was established in June 2007 to monitor compliance against waiting times targets).

This information is not held centrally.

In the UK, there is an alternative licensed product, OncoTICE, manufactured by MSD. Limited supplies of OncoTICE are now available directly from the manufacturer.